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Since the discovery that epidermal cell-derived thy­
IDocyte-activating factor was identiical to interleukin 
(1L)-1a and -p in 1986. these IDolecules have been 
iIDplicated in the pathogenesis of skin diseases. In 
1995 . it has becoIDe clear that ill group of gene 
products function to regulate the activity of IL-1. 
IL-1a and mature 17-kD IL-1P (cleaved from precur­
sor by IL-1fJ-converting enzyme) hind to the type 1 
IL-1 receptor to transduce a signal .. This process can 
be antagonized at the level of the� receptor by two 
distinct forms of the IL-1 receptor ,Ilntagonist. which 
bind to the type I receptor but do not transduce a 
I nterleukin (IL)-l is a pleiotropic proinflammatory cyto­kine that was defined as a "primary" cytokine based upon the prediction that its release, as an isolated event, would be sufficient to induce inflammation. In the past several years, it has become clear that ther,e are multiple ligands 
for IL-l receptors, some of which are agonists and others of 
which are antagonists . In addition, a nOll-signal-transducing 
receptor that efficiently binds IL-l agonislts has been identified 
(Table I). These multiple molecules fonn the IL-I family of 
agonists and antagonists . Much of this report will detail the in 
vitro and in vivo regulation of IL-l family members that are 
believed to influence the outcome of a putative IL-I-mediated 
event. For the purposes of this discussion, an IL-l-mediated 
event is defined as a consequence of the interaction of an active 
IL-l species (defined below) with its signal-transducing (type I) 
receptor. Before these issues are analyzed jin detail, it is instruc­
tive to discuss precisely how IL-l so efficiently localizes inflam­
mation. The putative sequence of events following the release of 
keratinocyte IL-I into the epidermis and dennis has been 
discussed in detail previousl y and is outlined below. 
IL-l is a potent inducer of endothelial adhesion-molecule ex­
pression [1-4], leading to endothelial cell surface expression of 
P-selectin, E-selectin, intercellular adhesion molecule-l (ICAM-I), 
and vascular cell adhesion molecule 1 (VCAM-l). The de novo 
expression of endothelial selectins, and their interaction with 
counter-receptors on leukocytes, are now accepted as important 
initial requirements for leukocyte extravasation [5). Several groups 
have now demonstrated that neutrophils and myelomonocytic cell 
lines can bind and roll on monolayers of selectin-expressing 
endothelial cells at flow rates that approximate flow through 
post-capillary venules [6]. Very recently, we have demonstrated 
that T cells can roll on endothelial selectins [I']. Whether T cells (or 
other cells expressing very late activation antigen 4 [VLA-4]) can 
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signal. The process can also be antagonized at the 
level of the ligand by either cell-bound or soluble 
type 2 IL-1 receptor. This type 2 IL-1 receptor binds 
ligand but does not transduce a signal. Keratinocytes 
can make each of these variables in vitro, and the 
balance between agonists and antagonists dictates 
the biologic outcome of a putative IL-1-mediated 
event. Transgenic mice that overexpress each of 
these factors individually in epidermis will be useful 
for enhancing our understanding of the cutaneous 
biology oflL-1.] Invest Dermatol105:62S-66S, 1995 
bypass the requirement for selectins is unclear, as recent reports 
have suggested that certain integrin/CAM interactions may be 
sufficient for initial selectin-independent tethering interactions [8]. 
This process would, however, involve VLA-4/VCAM-l interac­
tions and thus is still influenced by IL-l. 
The attachment and rolling under conditions of flow are required 
for subseqnent events leading to extravasation [5]. The first of these 
events involves activation of the leukocyte, which is achieved via 
the interaction of chemokines produced locally in tissue with their 
receptors on leukocytes. These chemokines (e. g., monocyte che­
motactic factor 1 [MCP-l], IL-8, gro-a; reviewed in [9]), all of 
which are induced by IL-l in vitro, can both activate the leukocyte 
at the vessel wall [5] and provide a chemotactic gradient such that 
when the leukocyte extravasates, it will be guided toward the 
original site of injury (i .e., the original site ofIL-l release). It now 
appears that chemokines bind avidly to glycosaminoglycans [5,10]. 
such that immobilized chemokines can decorate the luminal aspect 
of the endothelium in a perfect position to activate leukocytes 
rolling on endothelial selectins. The gradient fonned in the dennis 
can be fixed in place in situ by virtue of chemokine binding to 
dermal glycosaminoglycans, and this gradient can persist in the 
absence of continued chemokine production by injured cells. 
Mter the leukocyte has slowed to a roll on endothelial selectins 
and has been activated by locally produced chemokines, it will bind 
via VLA-4 or leukocyte-function associated antigen- l (depending 
on cell type and circumstances) to endothelial VCAM-l and 
ICAM-l or -2, respectively [5]. The cytoplasmic domains of these 
integrins are linked to the actin cytoskeleton of the leukocyte [11], 
and in response to chemokine-mediated gradients, the leukocyte 
will insinuate itself between endothelial cells, cross the endothelial 
basement membrane, and emerge into the dennis on the abluminal 
side of the vessel. Given that IL-l can orchestrate these events, it 
would appear potentially dangerous for nature to place constitu­
tively high levels of IL-la in the epidennis at all times. Recent 
advances in understanding the regulation of IL-l activity under­
score that this is one of the most highly regulated cytokine systems 
known (Fig 1). 
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Table I. Agonists and Antagonists of IL-I-Mediated 
Biologic Events 
Agonists Antagonists 
IL-la (17 kD, 31 kD) 
IL-1f3 (17 kD) 
IL-l receptor (type 1) 
IL-1 receptor antagonist 
Intracellular (icIL-lra) 
Secreted (sIL-lra) 
IL-l receptor (type 2) 
Cell surface 
Soluble 
BIOLOGIC FORMS OF IL-l 
IL-la and -{3 are both transcribed from genes on chromosome 2 in 
man and in mouse [12,13] and are translated as 31-kD proteins 
lacking a leader sequence and signal peptide [14,15]. It appears that 
they are not glycosylated (clearly they do not enter the Golgi 
complex or the rough endoplasmic reticulum; see [15,16]), and 
post-translational modification appears to consist largely of myris­
toylation for IL-la [17] and proteolytic cleavage with subsequent 
activation for lL-l{3 [18,19]. Although both 31-kD and processed 
17-kD IL-la bind to the IL-l receptor 1 (IL-IR1) and transduce 
signal [20], only 17-kD (and not 31-kD) 1L-1{3 binds and transduces 
a signal [20]. The proteolytic cleavage ofIL-1{3 is cell-type specific 
[19,21]; monocytes contain an enzyme (1L-1{3-convemng enzyme) 
that cleaves 31-kD IL-1{3 to form an N-terminal Ala-117 IL-l{3 
[21 ]. Although keratinocytes do not contain this enzyme activity 
and thus cannot process 31-kD IL-l intracellularly [22], release of 
31-kD IL-l{3 into a milieu containing proteases with chymotryptic 
specificities (e.g., mast cell chymase or cathepsin G) leads to 
generation of an active N-terminal Val-114 species of 1L-1{3 [22]. 
The precise mechanism of release of IL-l from cells remains 
enigmatic and has been incompletely explained [16,23]. Like basic 
fibroblast growth factor, 1L-1 is released most completely from cells 
that are physically disrupted. However, there is growing evidence 
for the existence of alternative secretion mechanisms for molecules 
like IL-la, IL-l{3, and basic fibroblast growth factor that lack a 
signal peptide [24-26]. These are phylogenetically ancient trans­
port pathways, and homologues of the pathways can be found in 
bacteria. Thus, the hypothesis that IL-l will only exit cells as a 
result of cell death may no longer be tenable [12-14]. Under certain 
circumstances, IL-la may be localized to the cell membrane by 
protein myristoylation [17,27], although whether the membrane­
associated product is oriented in such a way that it can interact with 
the IL-IRl on adjacent cells is speculative. Cells that contain the 
IL-l{3- convemng enzyme (e.g., monocytes) appear to be able to 
release the 17-kD form of IL-l{3 readily, although the precise 
transport mechanism has not been identified [16] . A recent report 
suggested that cells undergoing apoptosis acquire the capacity to 
release IL-l more efficiendy before cell death [28]. The precise 
transport pathway that permits IL-l "secretion" from cells is the 
subject of intensive study, but there is no longer serious doubt that 
such a pathway exists [23]. 
THE IL-l RECEPTOR ANTAGONIST (IL-lra) 
A unique molecule first cloned and characterized in 1990 functions 
as a pure antagonist of biologically active IL-l [29,30]. The IL-lra 
gene resides near genes encoding for IL-la and -{3 on chromosome 
2 in man [31] and bears certain homology to these molecules. 
However, the IL-lra binds to the IL-IRl nearly irreversibly 
without triggering signal transduction [32,33], thus temporarily 
removing the bound receptor from subsequent participation in 
IL-l-mediated signal transduction, The form of the IL-lra first 
described was a product of monocytes [34], and it is the only ligand 
for the IL-IR that can be efficiendy secreted from cells. This 
secreted IL-lra, or sIL-lra, contains a leader sequence and signal 
peptide, is post-translationally modified in the Golgi complex, and 
is released by cells through a classic secretion pathway [34,35]. It 
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Figure 1. Interleukin 1 axis in skin. 
acquire binding activity [31]. This is the only "cytokine" known to 
function as a pure antagonist without any identifiable partial agonist 
function [31]. 
After the discovery of the sIL-lra, it was noted that keratinocytes 
and other epithelial cells contained an 18-kD intracellular IL-l 
inhibitory activity that was not efficiendy secreted [36,37]. This 
activity was later identified as an alternatively spliced product of the 
same IL-lra gene that generates sIL-lra [37]. Called intracellular 
IL-lra, the 5' end of mature mRNA from this species arises from 
the 3' end of exon 1, several kilobase pairs upstream from the exon 
2 start site of sIL-lra [38]. This alternative splicing of the parent 
transcript ultimately generates a protein that contains an additional 
seven N-terminal amino acids and lacks the signal peptide and 
leader sequence intrinsic to sIL-lra [37]. Thus, this 18-kD molecule 
resembles IL-la and -{3 in that it resides in a cell-associated 
compartment, lacks a leader sequence and signal peptide, and 
cannot be secreted by conventional pathways. In addition, it is not 
glycosylated or otherwise post-translationally modified [38]. It is 
likely to be released by the same nonclassic transport pathway as 
IL-la and -{3 [16,23]. 
The presence of both IL-la and the intracellular IL-lra inside 
keratinocytes seems to represent a paradox; after all, when a 
keratinocyte is either induced to secrete or is lysed, it releases both 
agonist and antagonist, and the biologic consequences are unpre­
dictable. Indeed, the wisdom of this arrangement remains elusive. 
However, the very fact that epidermal cell-derived thymocyte­
activating factor/IL-l activity was discovered at all in keratinocyte 
cultures, where antagonist is more abundant than agonist, and the 
multiple demonstrations that epidermis contains measurable bioac­
tive IL-la, indicate that regardless of the outcomes predicted by 
molar ratios, the agonist effect of IL-l clearly dominates. In some 
systems, the ratio of antagonist to agonist (or IL-I/IL-lra) must be 
greater than 100:1 for complete blockade oflL-l-inducible events 
[39], but partial inhibition is seen at lower ratios [39,40]. It is likely 
that although biologically available quantities of the IL-lra may be 
insufficient to block completely IL-l-inducible events in vivo, the 
presence of IL-l and IL-lra may modifY the strength of IL-l­
inducible responses. There is no doubt, however, that pharmaco­
logic doses of the IL-lra can strongly inhibit IL-l activity [41,42], 
and it is difficult to imagine that the physiologic role ofIL-lra does 
not involve homeostasis of the IL-l axis [39,43]. 
THE IL-l RECEPTORS 
The IL-IRl is the sole known signal-transducing receptor for IL-l 
[44;45]. It is a variably glycosylated 80-kD molecule with a 
cytoplasmic domain of 215 amino acids [44]. It appears that all cells 
that respond to IL-l express the IL-IR1, based on blocking 
experiments performed with neutralizing IL-IRl and IL-IR2 
antibodies [44-46]. The mechanism ofIL-l-mediated signaling is 
currently the subject of intense study. 
In general, ligand activation of receptors is assumed to occur 
either by induced receptor aggregation or by ligand-binding­
related conformational changes transmitted by the extracellular and 
transmembrane parts of the receptor to the cytoplasmic domain. A 
considerable body of evidence suggests that IL-l-induced signal 
transduction occurs by the second mechanism. Cross-linking ex­
periments have not demonstrated receptor aggregation such as that 
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seen with epidermal growth factor or platelet-derived growth 
factor receptors in similar studies [47,48]. Furthermore, anti-IL­
lRl antibodies showed rio capacity to induce responses in cells 
sensitive to IL-1. Finally, as few as one to 10 IL-1 molecules bonnd 
per cell are required to trigger signaling [49-51], an unusually 
efficient mechanism that would be unlikely to result from aggre­
gation of widely spaced receptors. The structure of the receptor 
itself[ 46,52,53] gives little clue as to the mechanism of action. For 
exru:uple, the cytoplasmic domain bears no resemblance to known 
protein kinases [54], and immnnoprecipitated receptor shows no 
protein kinase activity [55]. Transfection experiments have dem­
onstrated that the cytoplasmic domain is required for receptor 
function [56], and the IL-1R2, which has a truncated cytoplasmic 
domain, does not transduce a signal. A variety of signaling pathways 
have been implicated in the IL-l response, including arachidonic 
acid [57-61], protein kinase C [62,63], cyclic adenosine mono­
phosphate [64,65], and ceramide [66], but in many cases the 
evidence is coriflicting. 
Very recent data have suggested that the IL-IRl activates a 
novel protein kinase cascade that results in the phosphorylation of 
a variety of proteins, including the 27-kD heat shock protein 
HSP27 [67-69]. The mechanism underlying this has now been 
studied in some detail, and it is apparent that three enzymes ofMW 
35, 40, and 50 kD are sequentially phosphorylated; the latter two 
have been purified to near homogeneity. The system closely 
resembles, but is molecularly distinct from, the microtubule assem­
bly protein kinase cascade [70], and the amplification that likely 
results from sequential activation of these kinases is likely to 
contribute to the exquisite sensitivity of the IL-l response. 
The IL-IR2 encodes a 68-kD molecule that was initially cloned 
and characterized on B cells and hematopoietic cells [71-74]. It 
binds to IL-l� but does not appear to transduce a signal [44,45]. It 
is now clear that this receptor is much more widely distributed and 
is present on epithelial cells, including keratinocytes [75,76]. The 
most revealing feature of this receptor is its short cytoplasmic tail 
(29 amino acids) and the lack of any evidence that it transduces a 
signal [44,45] . Unlike the IL-IR1, which cannot be regulated 
efficiently [75-77], the IL-IR2 can be regulated dramatically by 
various stimuli [78,79]. Its function appears to be to antagonize the 
biologic e1fects IL-l. Of note, it can be shed very efficiently from 
cells including keratinocytes [76,80]. Intuitively, it would seem that 
this shed receptor would be significantly inhibitory to IL-l­
mediated responses. Additional evidence supporting this notion 
derives from observations that vaccinia and cowpox viruses pro­
duce factors homologous to the IL-IR2 [81,82] . These soluble 
receptor-like molecules e1fectively bind to human IL-l{3 and inhibit 
IL-l-mediated inflammation [82]. It was proposed that viruses have 
exploited this product to reduce host defenses after their initial 
infection, thus favoring establishment [82]. 
Although much work has been done on the regulation of 
125I_IL-l ligand binding to cells, including keratinocytes, many of 
these studies were performed before it became clear that there were 
two distinct IL-1 receptors, arid the vast majority were not inter­
preted against the backgronnd of recent evidence that IL-IR2s are 
nonfnnctional [44,45,83-85]. It is clear from multiple experiments, 
however, that enhanced expression of IL-1Rl can lead to increased 
sensitivity to extracellular IL-l [86,87] . One study in particular 
indicated that transfection of IL-1Rl into cells deficient in this 
receptor rendered them responsive to quantities of IL-l three 
orders of magnitude lower than quantities of IL-1 to which the 
wild-type cells responded [86]. Many cells in which large increases· 
ofIL-lR were demonstrated after stimuli showed up-regulation of 
IL-1R2s, or at least a combination ofIL-IRl and IL-IR2 [75,76]. 
One exception is the illustration that platelet-derived growth factor 
can up-regulate IL-IR levels fivefold on fibroblasts [87]; these cells 
probably do not express IL-IR2s [88,89] and thus this variation can 
be reliably attributed to IL-IRI. Very recently, cloning and analysis 
of the promoter region of the IL-lRl were accomplished [77]. 
Surprisingly, the promoter resembled that of a number of so-called 
"housekeeping" genes, suggesting that regulation of this receptor is 
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likely to be limited. Indeed, we have fonnd that stimuli that 
up-regulate specific 125I_IL-l binding to human keratinocytes 
change IL-1R2 expression dramatically and IL-1Rl expression less 
so [76]. It appears that much more energy is spent preventing 
responses to IL-l at the level of the receptor than allowing them to 
occur more efficiently. Thns, antagonists of IL-l and non-signal­
transducing receptors (IL-IR2) are both produced most abnndantly 
by cells that also produce IL-l [91]. 
A primary function ofIL-lR2s is to be shed from cells to serve 
as a soluble scavenger of active IL-l as well as pro-IL-l{3 molecules 
[76,80,82]. It is not difficult to nnderstand the relevance of this 
factor to the epidermal microenvironment [2,90]. It would seem 
intuitively correct that, if cell surface IL-IRl remained constant, 
concurrent high-level expression of IL-IR2 on the same cells 
would make them less sensitive to activation by a constant level of 
extracellular IL-1. Preliminary studies have shown that antibodies 
that block IL-IR2 binding do enhance the responsiveness of 
keratinocytes to IL-1. A working hypothesis, then, is that whether 
shed or retained on the cell surface, IL-IR2s have a generally 
inhibitory activity. 
Since the discovery of keratinocyte-derived IL-l [91,92], hy­
potheses about the role of IL-l in skin disease have abonnded. 
Increased or decreased levels of di1ferent members of the IL-l axis 
have been reported in cutaneous T-cell lymphoma [93], contact 
hypersensitivity [94,95], acne vulgaris [96], scleroderma [97], hu­
man innn nodeficiency virus-l-associated skin diseases [98] , graft 
versus host disease [99,100], Kawasaki disease [101], melanoma 
[102], epidermal carcinogenesis [103,104], and psoriasis vulgaris 
[75,105-107]. It is important to stress that these studies report 
correlations between levels of individual IL-1 family molecules and 
clinical/histopathologic diagnoses. The relation ofIL-l and related 
molecules (or other cytokines, for that matter) to the pathogenesis 
of arty of these diseases remains hypothetical. 
TESTING THE PRIMARY CYTOKINE HYPOTHESIS 
USING TRANSGENIC MICE 
The advantages of using transgenic mice to prove hypotheses about 
the authentic role of proinflammatory molecules in skin are sub­
stantial. Using promoters that direct the expression of transgenes in 
a tissue-specific fashion, it is possible to overexpress individual 
molecules in particular tissues. A series of transgenic mice from our 
laboratories have been made using the keratin-14 promoter. These 
studies have shown that expression of adhesion molecules such as 
ICAM-l [108] or costimulatory molecules such as B7-1 [109] are 
not sufficient to induce infiammation. Similarly, overexpression of 
the chemokines MCP-l and gro-a in basal epidermis does not 
provoke spontaneous inflammation [110], though such chemokines 
can alter the course of elicited inflammation in a predictable 
fashion. However, transgenic mice that overexpress the primary 
cytokines IL-la arid tumor necrosis factor-a in basal epidermis do 
develop inflammation and skin disease, thus providing in vivo proof 
that primary cytokines are sufficient to induce inflammation. A 
series of additional transgenic mice have been constructed that 
overexpress each member of the IL-l axis in basal epidermis. We 
predict that mice that overexpress the IL-lra and the IL-IR2 in 
basal epidermis will resist IL-l-mediated inflammation, whereas 
mice that overexpress the IL-IRI will be more sensitive to IL-1. 
Although preliminary results suggest that these predictions are 
correct, these transgenic lines must be analyzed much more 
extensively before definitive statements can be made about IL-l 
family members in the epidermis. 
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